Anavex Life Sciences Corp.

265 articles with Anavex Life Sciences Corp.

• 

  Clinical Catch-Up: June 21-25

  6/28/2021

  It was a busy week for clinical trial news. Here’s a look.

• Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial

  6/28/2021

  ANAVEX ® 2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints CoA (p = 0.029) and MDS-UPDRS Part III (p = 0.024) and MDS-UPDRS Total (p = 0.038) 14.51-point MDS-UPDRS (Movement Disorder Society- Unified Parkinson Disease Rating Scale) Total score improvement compared to placebo (p = 0.034) Data strengthens regulatory pathway for Parkinson’s d

• Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

  6/24/2021

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), , today announced the closing of its previously announced registered direct offering to Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock

• Anavex Life Sciences Announces $50 Million Registered Direct Offering

  6/22/2021

  Anavex Life Sciences Corp. announced that it has entered into a definitive purchase agreement with Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock at a purchase price of $21.00 per share of common stock, a registered direct offering.

• Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

  6/21/2021

  Anavex Life Sciences Corp. reported predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary clinical efficacy endpoints from the U.S. Phase 2 randomized, double-blind, placebo-controlled trial of ANAVEX®2-73 in adult female patients with Rett syndrome.

• Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease

  6/14/2021

  Anavex Life Sciences Corp. reported that ANAVEX®2-73 and ANAVEX®3-71 are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets, titled “The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer's”.

• Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease

  6/8/2021

  Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, announced that it has exceeded its enrollment target for the ANAVEX®2-73 Phase 2b/3 study in Alzheimer’s disease.

• Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions

  6/3/2021

  Issuance of Its Newest U.S. Patent Will Strengthen Anavex’s Compounds Intellectual Property Portfolio

• Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

  5/26/2021

  Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors.

• Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business OutlookConference Call and Webcast Today at 4:30 p.m. ET

  5/13/2021

  Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, reported financial results for its fiscal quarter ended March 31, 2021.

• Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021Conference Call and Webcast To be Held Thursday, May 13, 2021 4:30 pm Eastern Time

  5/6/2021

  Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2021 on Thursday, May 13, 2021.

• Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development

  5/5/2021

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senior Vice President for Nonclinical Development

• Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference

  4/26/2021

  Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the B. Riley Securities’ Virtual Neuroscience Conference on Wednesday, April 28, 2021 at 12:00 p.m. EDT.

• Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome

  4/12/2021

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease,

• Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference

  4/8/2021

  Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 8:45 a.m. EDT.

• Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021

  4/7/2021

  Anavex Life Sciences Corp. announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Establishing Mutually Beneficial Collaborations,” at the World EPA Congress 2021 event on Thursday, April 15th at 8:55 a.m. EDT.

• Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

  3/31/2021

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome

• Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

  3/16/2021

  Anavex Life Sciences Corp. reported that ANAVEX®2-73 is featured in a recent peer-reviewed publication in the journal of Neuropharmacology, titled “Future avenues for Alzheimer’s disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery” from the series of the special issue on ’The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders’.

• Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease,

• Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®Rare Disease Day® at NIH will be held virtually on Monday, March 1, 2021, from 10:30 a.m. to 5:30 p.m. EST

  2/22/2021

  Anavex Life Sciences Corp. will join the panel, on Monday, March 1st at 11:35 a.m. EST. There will be a live Q&A following the panel discussion.